Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs

Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Sangeun, Ko, Meehyun, Lee, Jihye, Choi, Inhee, Byun, Soo Young, Park, Soonju, Shum, David, Kim, Seungtaek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318052/
https://www.ncbi.nlm.nih.gov/pubmed/32366720
http://dx.doi.org/10.1128/AAC.00819-20
_version_ 1783550758162006016
author Jeon, Sangeun
Ko, Meehyun
Lee, Jihye
Choi, Inhee
Byun, Soo Young
Park, Soonju
Shum, David
Kim, Seungtaek
author_facet Jeon, Sangeun
Ko, Meehyun
Lee, Jihye
Choi, Inhee
Byun, Soo Young
Park, Soonju
Shum, David
Kim, Seungtaek
author_sort Jeon, Sangeun
collection PubMed
description Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC(50)s), and in particular, two FDA-approved drugs—niclosamide and ciclesonide—were notable in some respects.
format Online
Article
Text
id pubmed-7318052
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-73180522020-07-10 Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs Jeon, Sangeun Ko, Meehyun Lee, Jihye Choi, Inhee Byun, Soo Young Park, Soonju Shum, David Kim, Seungtaek Antimicrob Agents Chemother Antiviral Agents Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC(50)s), and in particular, two FDA-approved drugs—niclosamide and ciclesonide—were notable in some respects. American Society for Microbiology 2020-06-23 /pmc/articles/PMC7318052/ /pubmed/32366720 http://dx.doi.org/10.1128/AAC.00819-20 Text en Copyright © 2020 American Society for Microbiology. All Rights Reserved (https://doi.org/10.1128/ASMCopyrightv2) . https://doi.org/10.1128/ASMCopyrightv2 This article is made available via the PMC Open Access Subset for unrestricted noncommercial re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Antiviral Agents
Jeon, Sangeun
Ko, Meehyun
Lee, Jihye
Choi, Inhee
Byun, Soo Young
Park, Soonju
Shum, David
Kim, Seungtaek
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
title Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
title_full Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
title_fullStr Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
title_full_unstemmed Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
title_short Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
title_sort identification of antiviral drug candidates against sars-cov-2 from fda-approved drugs
topic Antiviral Agents
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318052/
https://www.ncbi.nlm.nih.gov/pubmed/32366720
http://dx.doi.org/10.1128/AAC.00819-20
work_keys_str_mv AT jeonsangeun identificationofantiviraldrugcandidatesagainstsarscov2fromfdaapproveddrugs
AT komeehyun identificationofantiviraldrugcandidatesagainstsarscov2fromfdaapproveddrugs
AT leejihye identificationofantiviraldrugcandidatesagainstsarscov2fromfdaapproveddrugs
AT choiinhee identificationofantiviraldrugcandidatesagainstsarscov2fromfdaapproveddrugs
AT byunsooyoung identificationofantiviraldrugcandidatesagainstsarscov2fromfdaapproveddrugs
AT parksoonju identificationofantiviraldrugcandidatesagainstsarscov2fromfdaapproveddrugs
AT shumdavid identificationofantiviraldrugcandidatesagainstsarscov2fromfdaapproveddrugs
AT kimseungtaek identificationofantiviraldrugcandidatesagainstsarscov2fromfdaapproveddrugs

Ejemplares similares